{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/conjunctivitis-allergic/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"b1dc6613-43b4-55fe-9216-a83aab0ef918","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 75bdb86a-4435-429c-a14c-3ad282d3c8c4 --><h2>Changes</h2><!-- end field 75bdb86a-4435-429c-a14c-3ad282d3c8c4 -->","summary":null,"htmlStringContent":"<!-- begin item 7c4d3646-3f5e-4894-b4d3-1b492a6a93c9 --><!-- begin field 95bf6919-9b04-4a48-8040-8b7f257c372b --><p><strong>October 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>May 2017 </strong>— reviewed. A literature search was conducted in March 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made.</p><!-- end field 95bf6919-9b04-4a48-8040-8b7f257c372b --><!-- end item 7c4d3646-3f5e-4894-b4d3-1b492a6a93c9 -->","topic":{"id":"b4698c45-6b7c-5244-836f-430591327957","topicId":"27f540e5-bb8e-4cee-a0aa-be515efa4fc2","topicName":"Conjunctivitis - allergic","slug":"conjunctivitis-allergic","lastRevised":"Last revised in October 2020","chapters":[{"id":"bc756208-c2a7-5b33-a4cb-67c41a75ecb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6470bf56-596c-5d66-b2b2-ba79590bb255","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"17755f2a-0980-50f9-b62e-a34968c9682e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b1dc6613-43b4-55fe-9216-a83aab0ef918","slug":"changes","fullItemName":"Changes"},{"id":"ba5e8d6b-90f7-5b69-b09a-2bb0c2692918","slug":"update","fullItemName":"Update"}]},{"id":"fee1ca82-9d2a-50a4-9230-1a93482b8b4f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3d036930-da50-5ea2-82e1-1d0fb936a8b4","slug":"goals","fullItemName":"Goals"},{"id":"9ba6a0ce-0eae-5442-85f0-81f7ff71345b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"48935dfe-bca1-53fa-8d50-fa978331bd56","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35b962f0-ec6b-53c9-b6f2-a5783ae10716","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8e9984f4-8c0d-5231-9eec-91a9fb49ecc4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8fa3b231-6e2b-5fa2-aa0c-eb5359ff8160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ebf46a5d-2a79-5df8-82dd-d23fcb0559f1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"67185462-9d0a-5b7d-b8af-80b8958f2420","slug":"definition","fullItemName":"Definition"},{"id":"1c320f1a-b91f-5d5b-a47b-dc0094518883","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b21baf96-f39b-5eeb-934b-c193a434933d","slug":"causes","fullItemName":"Causes"},{"id":"923b6415-5fe1-550a-baf5-89285f8ddf77","slug":"complications","fullItemName":"Complications"},{"id":"a679bff6-4749-539e-bdb0-a762a9f91728","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a7d99d63-f47f-54bf-a60f-8ae6f2a42fb9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"089d5cf7-0f6b-521b-88c1-d4f25eef7101","slug":"assessment","fullItemName":"Assessment"},{"id":"7bb8bdb4-0279-5783-ba21-e44e8bcd0832","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a95dbd6-aaa4-5d6a-aa5b-9635d279f9a0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"51e7c1d5-cd3d-5dea-a8ec-5a38deb58245","fullItemName":"Management","slug":"management","subChapters":[{"id":"e4ced49a-4b06-5559-9efb-c708812a8065","slug":"referral","fullItemName":"Scenario: Referral"},{"id":"77a507ec-4dff-5204-b375-121264b0adf8","slug":"management-in-primary-care","fullItemName":"Scenario: Management in primary care"}]},{"id":"452bc42e-1fe8-56e6-8511-57362d05fe3f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f9e89c16-d4a7-5241-86f6-1f78eacc68fa","slug":"topical-ocular-antihistamines-mast-cell-stabilizers","fullItemName":"Topical ocular antihistamines and mast cell stabilizers"},{"id":"f9a1678c-7117-5852-af35-628b676780c8","slug":"mast-cell-stabilizers","fullItemName":"Mast cell stabilizers"}]},{"id":"a32b7db8-1764-58b8-adbb-ab8ce0f44e46","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd1a2d20-e91f-51f1-a2a2-486ebf015f65","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bc4e76de-c203-5f3e-ad9a-b84d6bc9d81e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"565b3a01-b21e-5837-b9f1-49fda55982ad","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b08973ef-af46-5e6f-b85c-d0bd9ca40bab","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3003e52e-8597-505e-a3ce-e46fde4c0c20","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b7947929-e2f9-50c7-b5cd-3e34b802bae1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3819cbbb-ca8c-58b7-b608-0a9567c5d5b5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"17755f2a-0980-50f9-b62e-a34968c9682e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"97f327f0-2ab5-5346-ae5b-7045defbc119","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field c5507594-2db2-4bf9-af33-3d253c10d870 --><h3>Previous changes</h3><!-- end field c5507594-2db2-4bf9-af33-3d253c10d870 -->","summary":null,"htmlStringContent":"<!-- begin item f10ab9e6-c8ff-450a-ab31-82f8f57530d8 --><!-- begin field 30151845-3a25-421e-9cde-7d5fe4011279 --><p><strong>August 2012 </strong>— reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Changes to the recommendations include:</p><ul><li>Olopatadine and epinastine are no longer black triangle drugs. This information has been removed from the text, and these drugs have been included in the recommendations. Prescriptions for olopatadine 0.1% eye drops and epinastine 500 micrograms per mL eye drops have been added.</li><li>The recommendation to prescribe oral corticosteroids in primary care has been removed to reflect the current literature and expert opinion from external reviewers.</li></ul><p><strong>March 2011 </strong>— minor update. A prescription for sodium cromoglicate 2% preservative-free eye drops (Catacrom<sup>®</sup>) has been included. Issued in March 2011.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>January 2009 </strong>— minor update. Otrivin-Antistin<sup>® </sup>eye drops are no longer recommended for use in children under 12 years of age; text and prescriptions updated. Issued in February 2009.</p><p><strong>August to November 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>July 2006 </strong>— minor update. Levocabastine products discontinued and prescriptions removed. Issued in July 2006.</p><p><strong>January 2006 </strong>— minor update. Black triangle removed from desloratadine. Issued in February 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>September 2004 </strong>— reviewed. Validated in November 2004 and issued in February 2005.</p><p><strong>August 2001 </strong>— reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>October 1998 </strong>— written, replacing guidance on <em>Acute atopic conjunctivitis.</em></p><!-- end field 30151845-3a25-421e-9cde-7d5fe4011279 --><!-- end item f10ab9e6-c8ff-450a-ab31-82f8f57530d8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}